CVS Health Corp (CVS) Shares Sold by Ycg LLC
Ycg LLC trimmed its position in CVS Health Corp (NYSE:CVS) by 0.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 79,348 shares of the pharmacy operator’s stock after selling 632 shares during the quarter. CVS Health makes up 1.4% of Ycg LLC’s holdings, making the stock its 23rd largest position. Ycg LLC’s holdings in CVS Health were worth $5,783,000 at the end of the most recent reporting period.
Several other hedge funds have also recently modified their holdings of CVS. FIL Ltd grew its stake in CVS Health by 13.8% in the 2nd quarter. FIL Ltd now owns 514,836 shares of the pharmacy operator’s stock valued at $41,424,000 after buying an additional 62,318 shares during the last quarter. ETRADE Capital Management LLC grew its stake in CVS Health by 3.7% in the 2nd quarter. ETRADE Capital Management LLC now owns 55,653 shares of the pharmacy operator’s stock valued at $4,478,000 after buying an additional 1,979 shares during the last quarter. Ally Financial Inc. grew its stake in CVS Health by 20.0% in the 2nd quarter. Ally Financial Inc. now owns 90,000 shares of the pharmacy operator’s stock valued at $7,241,000 after buying an additional 15,000 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt grew its stake in CVS Health by 17.9% in the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 77,859 shares of the pharmacy operator’s stock valued at $5,645,000 after buying an additional 11,800 shares during the last quarter. Finally, Prudential Financial Inc. grew its stake in CVS Health by 13.1% in the 3rd quarter. Prudential Financial Inc. now owns 3,332,567 shares of the pharmacy operator’s stock valued at $271,004,000 after buying an additional 386,036 shares during the last quarter. 83.11% of the stock is currently owned by institutional investors.
CVS has been the topic of a number of research reports. Jefferies Group set a $76.00 price target on shares of CVS Health and gave the company a “hold” rating in a research note on Monday, December 4th. Robert W. Baird decreased their target price on shares of CVS Health from $85.00 to $80.00 and set a “neutral” rating on the stock in a research report on Friday, February 9th. ValuEngine lowered shares of CVS Health from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. Vetr lowered shares of CVS Health from a “buy” rating to a “hold” rating and set a $77.11 target price on the stock. in a research report on Thursday, January 4th. Finally, Royal Bank of Canada set a $95.00 target price on shares of CVS Health and gave the stock a “buy” rating in a research report on Monday, December 4th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $87.03.
CVS Health (NYSE:CVS) last posted its quarterly earnings results on Thursday, February 8th. The pharmacy operator reported $1.92 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.88 by $0.04. The business had revenue of $48.39 billion for the quarter, compared to analyst estimates of $47.54 billion. CVS Health had a net margin of 3.58% and a return on equity of 17.21%. The firm’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter last year, the business posted $1.71 EPS. analysts forecast that CVS Health Corp will post 6.37 earnings per share for the current fiscal year.
In related news, EVP Lisa Bisaccia sold 29,445 shares of the stock in a transaction that occurred on Thursday, December 21st. The shares were sold at an average price of $75.00, for a total value of $2,208,375.00. Following the completion of the transaction, the executive vice president now owns 15,556 shares of the company’s stock, valued at approximately $1,166,700. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Helena Foulkes sold 19,965 shares of the stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $71.04, for a total transaction of $1,418,313.60. Following the completion of the transaction, the executive vice president now directly owns 65,072 shares of the company’s stock, valued at approximately $4,622,714.88. The disclosure for this sale can be found here. Company insiders own 0.61% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was first published by Daily Political and is owned by of Daily Political. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://www.dailypolitical.com/2018/03/05/cvs-health-corp-cvs-shares-sold-by-ycg-llc.html.
CVS Health Profile
CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.